Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarlowe Regulatory News (MRL)

Share Price Information for Marlowe (MRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 500.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 10.00 (2.041%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 500.00
MRL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Executive Incentive Plan and Notice of GM

10 May 2021 07:05

RNS Number : 0007Y
Marlowe PLC
10 May 2021
 

10 May 2021

Marlowe plc

 Executive Incentive Plan and Notice of General Meeting

Marlowe plc ("Marlowe", the "Group" or the "Company"), the UK leader in business-critical services and software which assure safety and regulatory compliance, announces that it has, subject to shareholder approval, adopted the Marlowe plc Executive Incentive Plan (the "EIP").

 

Since the Group's readmission to AIM in 2016, Marlowe has delivered significant growth through a combination of organic and acquisition-led performance. Having delivered on its initial five-year strategy in building a UK market-leading platform providing business-critical services and software which assure safety and regulatory compliance, the Group has a clearly defined strategy for continued organic and acquisition-led growth, targeting Group revenues of c.£500 million and adjusted EBITDA of c.£100 million over the next three years. The recent successful placing to raise c.£100 million before expenses means that the Company is well positioned to capitalise on acquisition opportunities as part of its defined strategy.

 

With Marlowe's historical 2016 Incentive Scheme having concluded in February 2021, and no other meaningful long term incentive scheme currently in place, the Remuneration Committee has considered appropriate options for incentivising the Company's senior executive team in the next phase of Marlowe's growth and is now proposing the adoption of the EIP.

 

The EIP will form the cornerstone of the Company's remuneration structure to retain and motivate the senior management team, focusing them on long term value creation and aligning their interests directly with shareholders.

 

In structuring the EIP, the Remuneration Committee has been advised by PricewaterhouseCoopers, who considers the plan to be fair and reasonable, and has considered the findings of the Executive Remuneration Working Group and the latest Principles of Remuneration published by the Investment Association and the QCA, whilst also ensuring that the EIP takes the most appropriate form for the Company's strategy and business needs. The proposed EIP (together with other share plans) operates within a 10% in 10 years dilution limit in line with corporate governance best practice.

 

In addition, the Board has had consultations with its major shareholders and has so far received positive indications of support for the EIP from shareholders representing over 45% of the Company ordinary shares, inclusive of the Directors who all intend to vote in favour.

 

Notice of General Meeting and posting of Circular

 

Whilst the Company does not require shareholder approval for its remuneration policy, the EIP is being put to a vote at a general meeting of the Company which will take place at 9.00 a.m. on 25 May 2021 at 20 Grosvenor Place, London SW1X 7HN (the "General Meeting"). A circular describing the EIP and convening the General Meeting is today being posted to shareholders and will shortly be available from the Company's website at www.marloweplc.com.

 

The EIP

 

Pursuant to the EIP participants will be awarded with performance units that will convert into new ordinary shares in the Company in the form of nil-cost options ("EIP Performance Units") at the end of a five-year performance period ending on 31 March 2026 (the "Performance Period"), provided that the value created for Marlowe shareholders during the Performance Period is in excess of a hurdle calculated by reference to 10% annualised growth in the Company's share price from the start of the Performance Period on 1 April 2021 based on an opening share price of £6.90 per share ("Threshold Hurdle").

 

Providing the Threshold Hurdle has been achieved by the end of the Performance Period, the EIP participants will be entitled to receive, in aggregate, 10% of the value created for shareholders above the Threshold Hurdle. This value sharing percentage will apply only to the ordinary shares in issue on 1 April 2021 and is capped at a maximum aggregate award of 4,902,295 new ordinary shares, subject to the Remuneration Committee retaining discretion to scale back the formulaic vesting of the EIP in line with corporate governance best practice.

 

As part of the implementation of the EIP, the Chief Executive and Chief Finance Officer have agreed they will receive below market salaries, will forgo an annual bonus and will not receive further incentives for the duration of the EIP.

 

Awards under the EIP will be subject to customary malus provisions during the Performance Period and to clawback for a period of 2 years post vesting.

 

Subject to shareholder approval of the EIP, Alex Dacre, the Company's Chief Executive, will be allocated 56.5% of the EIP Performance Units. Marlowe's new Chief Financial Officer, Adam Councell, will participate in the EIP when he joins the Board in the second half of Marlowe's FY22 financial year, and will be awarded 20% of the EIP Performance Units (but pro-rated for the proportion of the Performance Period he is a member of the Board). The remaining EIP Performance Units will be allocated to other senior executives. Mark Adams, the Company's current Group Finance Director who recently announced his retirement, and the Company's Non-Executive Directors will not participate in the EIP.

 

For further information:

 

Marlowe plc

www.marloweplc.com

 

Alex Dacre, Chief Executive

Tel: +44 (0) 203 813 8498

 

Mark Adams, Group Finance Director

IR@marloweplc.com

 

 

Cenkos Securities plc (Nominated Adviser and Joint Broker)

 

Nicholas Wells

Tel: +44 (0)20 7397 8900

Ben Jeynes

 

 

Berenberg (Joint Broker)

 

Ben Wright

 

Mark Whitmore

Tel: +44 (0)20 3207 7800

 

 

FTI Consulting

 

Nick Hasell

 

Alex Le May

Tel: +44 (0)20 3727 1340

 

 

 

About Marlowe plc

Marlowe is a UK leader in business critical services and software which assure safety and regulatory compliance. The Group was formed to create sustainable shareholder value through the acquisition and development of businesses that provide regulated safety and compliance services. It is focused on health & safety, compliance software, employment law & HR compliance, fire safety, security, water treatment & air hygiene and occupational health services - all of which are vital to the wellbeing of its customers operations and are invariably governed by regulation. Marlowe currently provides services to over 15% of Britain's commercial premises and is increasingly attractive to customers who require a single outsourced, nationwide, provider of a comprehensive range of regulated compliance and safety services. Our customers can be found in most office complexes, high streets & leisure facilities, manufacturing plants and industrial estates, and include thousands of SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGDKCBNFBKDKPK
Date   Source Headline
30th Apr 20247:00 amRNSTotal Voting Rights
8th Apr 20242:54 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
26th Mar 20244:45 pmRNSBlock listing Interim Review
18th Mar 20247:00 amRNSBoard Changes; Update re: Returns of Capital
26th Feb 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
22nd Feb 20247:00 amRNSDisposal and Directorate Change
15th Jan 202410:23 amRNSChange of Nominated Adviser and Joint Broker
30th Nov 20237:00 amRNSTotal Voting Rights
28th Nov 20237:00 amRNSInterim results for the six months to 30 Sept 2023
23rd Nov 20237:00 amRNSNotice of Interim Results
31st Oct 20234:30 pmRNSTotal Voting Rights
27th Sep 20235:18 pmRNSHolding(s) in Company
26th Sep 20233:23 pmRNSBlock Admission
13th Sep 20236:15 pmRNSResult of AGM
13th Sep 20237:00 amRNSAnnual General Meeting and Trading Update
4th Sep 20237:00 amRNSHolding(s) in Company
8th Aug 20237:00 amRNSExercise of Share Options and Total Voting Rights
7th Aug 20237:45 amRNSResponse to Speculation
4th Aug 20233:50 pmRNSHolding(s) in Company
3rd Aug 20235:25 pmRNSHolding(s) in Company
31st Jul 20233:30 pmRNSIssue of Equity and Total Voting Rights
26th Jul 20237:00 amRNSAcquisition of IMSM
18th Jul 202312:15 pmRNSCapital Reduction Effective
13th Jul 20232:00 pmRNSPublication of Notice of AGM and Annual Report
29th Jun 20237:00 amRNSPreliminary results
26th Jun 20237:00 amRNSNotice of Full Year Results
23rd Jun 20234:56 pmRNSHolding(s) in Company
19th Jun 202311:06 amRNSResult of General Meeting
5th Jun 20239:31 amRNSHolding(s) in Company
2nd Jun 20232:51 pmRNSPosting of Circular and Notice of General Meeting
2nd Jun 202312:36 pmRNSHolding(s) in Company
18th Apr 20231:45 pmRNSHolding(s) in Company
29th Mar 20237:00 amRNSCapital Markets Day Replay
28th Mar 20237:00 amRNSCapital Markets Day and Trading Update
7th Mar 20237:00 amRNSNotice of Capital Markets Event
28th Feb 20232:20 pmRNSHolding(s) in Company
26th Jan 20231:46 pmRNSHolding(s) in Company
5th Jan 20237:00 amRNSNotice of Capital Markets Event
2nd Dec 20229:00 amRNSNotice of Investor Presentation
1st Dec 202210:34 amRNSDirector/PDMR Shareholding
1st Dec 20229:00 amRNSDirector/PDMR Shareholding
24th Nov 20222:14 pmRNSDirector/PDMR Shareholding
24th Nov 20221:48 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSHalf-year Report
21st Nov 202212:54 pmRNSExercise of Share Options and Total Voting Rights
17th Nov 20227:00 amRNSNotice of Interim Results
2nd Nov 20225:08 pmRNSHolding(s) in Company
19th Oct 202210:40 amRNSExercise of Share Options and Total Voting Rights
14th Oct 20223:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.